Interaction between α-synuclein and other proteins in neurodegenerative disorders.
about
Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's diseaseCross dimerization of amyloid-β and αsynuclein proteins in aqueous environment: a molecular dynamics simulations study.Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States.α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairmentCSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's diseaseInteraction between pathogenic proteins in neurodegenerative disorders.From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease.Advances in electrochemical detection for study of neurodegenerative disorders.Neuropathology of multiple system atrophy: new thoughts about pathogenesis.Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample.Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.Concomitant accumulation of α-synuclein and TDP-43 in a patient with corticobasal degeneration.Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy.A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease.
P2860
Q28542628-C40E8281-6A73-4F9A-92E1-ECCDAFAE1C84Q34165988-2D756E35-963F-4742-B3EA-B4A240785484Q36139579-CBF0620F-427D-4242-8DC6-BB6101DF2C21Q36174698-91703110-9959-4B6F-B4DA-132050AA6EC1Q37083478-E7D6DCAB-C30D-4D97-A972-54648781DF11Q37086400-5F31035A-6736-4DBE-AE23-C94F92D736B2Q37266166-2EF5FA4F-DEE2-409E-8C27-6E8A928262E8Q37969262-0096E380-ECE8-4113-A08E-31F0B4262ABDQ38029575-2D41451F-99FD-419C-9516-ADC7215D56ADQ38093077-138D937F-A7AB-4664-ACCC-64E8B3780FD6Q38258246-CBBA3AEC-6A7E-4805-B18E-E0C98EEE6B55Q38311234-E9C96433-12D0-452C-85AD-98EB89FFD913Q38972171-2EB1CE7C-DD56-4CEA-99DA-A9DEA4503603Q40464051-4711373E-3BC9-421B-B81F-C4B8DBF0DCA5Q41785479-330F2108-9D10-45CF-82FB-47A8E3B4A983Q42509261-845C9FA4-65B0-4900-A94E-0EF03C05DF51Q48550467-F879418C-7277-4521-85E0-70CAE3283AFFQ49562668-2E8BF153-7CF4-4600-B6AB-8FC5E6EA14D2Q49613405-E12558C8-6233-445C-91F1-1EA9C0B6BCF9Q51762778-F212B9FC-45C6-4671-8672-64F46981E292Q55031216-AC92AE83-04E8-4EF1-9E7D-94BB904DA76A
P2860
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@en
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@nl
type
label
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@en
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@nl
prefLabel
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@en
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@nl
P2860
P921
P356
P1476
Interaction between α-synuclein and other proteins in neurodegenerative disorders.
@en
P2093
Kurt A Jellinger
P2860
P304
P356
10.1100/2011/371893
P407
P577
2011-10-24T00:00:00Z